Scholarlink

<p>Human adenovirus (HAdV), a leading cause of pediatric acute respiratory infections (ARIs), exhibited altered transmission patterns during the period of time in which COVID-19 nonpharmaceutical interventions (NPIs) were being applied. In this study, we investigated the molecular and clinical characteristics of pediatric HAdV infections in Hangzhou across two epidemiological phases: the 2022 group (March 2022–February 2023), representing a period of strict NPIs with initial post-policy adjustment, and the 2023 group (March 2023-February 2024), reflecting resumption of normal social activities. The retrospective analysis included 55,772 children (aged 0–16 years) with respiratory infections from the Children's Hospital of Zhejiang University School of Medicine. HAdV was detected via PCR‒capillary electrophoresis. Hexon gene sequencing and phylogenetic analysis were performed on 105 randomly selected HAdV-positive samples. In the 2022 group, the positivity rate of HAdV was 4.12% (579/14,049), whereas in the 2023 group, it was 3.59% (1,497/41,723). The peak HAdV infection rate occurred in May 2022 (6.39%, 61/955) and November 2022 (5.32%, 102/1,918). A sustained epidemic trend emerged after Oct. 2023, with a 6.08% (230/3,785) rate occurring in February 2024. HAdV-positive children were predominantly aged 3–6 years (<i>P</i> &lt; 0.001), with no significant difference in the proportion of male and female patients (<i>P</i> &gt; 0.05). The primary coinfections involved <i>Mycoplasma pneumoniae</i>. Pneumonia was the most common clinical diagnosis. Phylogenetic analysis classified 92.6% of the circulating strains as HAdV-B, with a small proportion of HAdV-C. These results offer vital evidence for optimizing the prevention and control of pediatric HAdV infections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular epidemiology and clinical characteristics of human adenovirus in children in Hangzhou (2022–2023)

  • 期刊论文

  • 发表日期：

    2026年1月22日

查看全文
  • Qin-rui Lai,
  • Wei Chen,
  • Guo-feng Yu,
  • Ya-jun Guo,
  • Shi-qiang Shang,
  • Wei Li

摘要

Human adenovirus (HAdV), a leading cause of pediatric acute respiratory infections (ARIs), exhibited altered transmission patterns during the period of time in which COVID-19 nonpharmaceutical interventions (NPIs) were being applied. In this study, we investigated the molecular and clinical characteristics of pediatric HAdV infections in Hangzhou across two epidemiological phases: the 2022 group (March 2022–February 2023), representing a period of strict NPIs with initial post-policy adjustment, and the 2023 group (March 2023-February 2024), reflecting resumption of normal social activities. The retrospective analysis included 55,772 children (aged 0–16 years) with respiratory infections from the Children's Hospital of Zhejiang University School of Medicine. HAdV was detected via PCR‒capillary electrophoresis. Hexon gene sequencing and phylogenetic analysis were performed on 105 randomly selected HAdV-positive samples. In the 2022 group, the positivity rate of HAdV was 4.12% (579/14,049), whereas in the 2023 group, it was 3.59% (1,497/41,723). The peak HAdV infection rate occurred in May 2022 (6.39%, 61/955) and November 2022 (5.32%, 102/1,918). A sustained epidemic trend emerged after Oct. 2023, with a 6.08% (230/3,785) rate occurring in February 2024. HAdV-positive children were predominantly aged 3–6 years (P < 0.001), with no significant difference in the proportion of male and female patients (P > 0.05). The primary coinfections involved Mycoplasma pneumoniae. Pneumonia was the most common clinical diagnosis. Phylogenetic analysis classified 92.6% of the circulating strains as HAdV-B, with a small proportion of HAdV-C. These results offer vital evidence for optimizing the prevention and control of pediatric HAdV infections.